102 related articles for article (PubMed ID: 35037561)
1. Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
Melén CM; Merrien M; Wasik AM; Panagiotidis G; Beck O; Sonnevi K; Junlén HR; Christensson B; Sander B; Wahlin BE
Leuk Lymphoma; 2022 Jun; 63(6):1387-1397. PubMed ID: 35037561
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
5. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
[TBL] [Abstract][Full Text] [Related]
6. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
7. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
8. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83.
Cerretani D; Collodel G; Brizzi A; Fiaschi AI; Menchiari A; Moretti E; Moltoni L; Micheli L
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752303
[TBL] [Abstract][Full Text] [Related]
12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
13. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
16. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.
Coulter C; Wagner JR
J Anal Toxicol; 2021 Sep; 45(8):807-812. PubMed ID: 34137890
[TBL] [Abstract][Full Text] [Related]
18. Homegrown perceptions about the medical use and potential abuse of CBD and THC.
McFadden BR; Malone T
Addict Behav; 2021 Apr; 115():106799. PubMed ID: 33387977
[TBL] [Abstract][Full Text] [Related]
19. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
